Drug Discovery Informatics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 - By Product, Technology, Grade, Application, End-user, Region:

Description

The global drug discovery informatics market is experiencing robust growth due to increased investments in novel research and development initiatives by pharmaceutical companies. A significant portion of time and financial resources is dedicated to drug discovery, using comprehensive bioinformatics algorithms to develop data pertaining to drugs, diseases, pathways, and gene expression. This innovative approach is leading to fresh perspectives and customized drug discovery, aimed at reducing the cost of drug development. The growing interest from pharmaceutical companies and the need to minimize discovery and development costs are expected to drive substantial growth in the global drug discovery informatics market.

Technological Advancements Augment Market Growth

Drug informatics analysis plays a vital role in speeding up the identification of target drugs and aids in drug candidate screening. It also facilitates the classification of side-effects and forecasting drug resistance. The use of high throughput molecular data, such as epigenetic, proteomic, genome architecture, and ribosome profiling, has had a notable impact on mechanism-based drug discovery. The application of informatics and simulation in drug development can significantly cut costs and optimize resource utilization. As a result, the adoption of informatics in drug discovery is creating new revenue streams and opportunities across the drug discovery informatics market.

Pharmaceutical Investments Drive Rapid Market Expansion

Pharmaceutical companies are making substantial investments in drug development to produce more effective and advanced drugs. The development of advanced throughput screening facilities and automated screening of large compound libraries are witnessing increased investments. These positive developments in biomedicine are set to expand the drug discovery informatics market, with support from the business, economic, and social sectors. This backing from the pharmaceutical industry is expected to drive significant growth in the drug discovery informatics market in the coming years.

North America to Lead the Global Drug Discovery Informatics Market

The United States leads in sophisticated R&D programs for drug discovery informatics, making North America the dominant region in the global market. The country has emerged as a pioneer in technological advancements, particularly in data mining and analytics for drug discovery. The healthcare and IT industries are actively involved in advancing informatics research to meet the demand for new drugs. As a result, North America is projected to witness stronger market growth compared to other regions during the assessment period.

Key Players in the Global Drug Discovery Informatics Market

The global drug discovery informatics market boasts a highly competitive landscape, with key players dominating the research-oriented sector. Notable market players include Jubilant Life Sciences Limited, Clarivate Analytics, Infosys, Accenture, PerkinElmer, IBM, GVK Biosciences, and Charles River Laboratories, among others.

1. Executive Summary

1.1. Global Drug Discovery Informatics Market Outlook, 2018 - 2030 (US$ Million)
1.2. Global Drug Discovery Informatics Market Incremental Opportunity, 2018 - 2030 (US$ Million)
1.3. Key Industry Trends

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Industry Challenges & Opportunities
2.3. PESTLE Analysis
2.4. Regulatory Framework
2.5. Covid-19 Impact Analysis

3. Global Drug Discovery Informatics Market Outlook, 2018 - 2030

3.1. Global Drug Discovery Informatics Market Outlook, by Service Type, Value (US$ Mn), 2018 - 2030
- 3.1.1. Key Highlights
  - 3.1.1.1. In-House
  - 3.1.1.2. Outsourced
- 3.1.2. BPS Analysis/Market Attractiveness Analysis

4. Global Drug Discovery Informatics Market Outlook, 2018 - 2030

4.1. Global Drug Discovery Informatics Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
- 4.1.1. Key Highlights
  - 4.1.1.1. Data Sequencing
  - 4.1.1.2. Target Data Analysis
  - 4.1.1.3. Molecular Docking
  - 4.1.1.4. Molecular Modelling
  - 4.1.1.5. Identification & Validation
  - 4.1.1.6. Others
- 4.1.2. BPS Analysis/Market Attractiveness Analysis
4.2. Global Drug Discovery Informatics Market Outlook, by End User, Value (US$ Mn), 2018 - 2030
- 4.2.1. Key Highlights
  - 4.2.1.1. Pharmaceutical & Biotech Companies
  - 4.2.1.2. Contract Research Organizations
  - 4.2.1.3. Research Institutes
  - 4.2.1.4. Others
- 4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. Global Drug Discovery Informatics Market Outlook, by Region, Value (US$ Mn), 2018 - 2030
- 4.3.1. Key Highlights
  - 4.3.1.1. North America
  - 4.3.1.2. Europe
  - 4.3.1.3. Asia Pacific
  - 4.3.1.4. Rest of the World
- 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. North America Drug Discovery Informatics Market Outlook, 2018 - 2030

5.1. North America Drug Discovery Informatics Market Outlook, by Service Type, Value (US$ Mn), 2018 - 2030
- 5.1.1. Key Highlights
  - 5.1.1.1. In-House
  - 5.1.1.2. Outsourced
- 5.1.2. BPS Analysis/Market Attractiveness Analysis
5.2. North America Drug Discovery Informatics Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
- 5.2.1. Key Highlights
  - 5.2.1.1. Data Sequencing
  - 5.2.1.2. Target Data Analysis
  - 5.2.1.3. Molecular Docking
  - 5.2.1.4. Molecular Modelling
  - 5.2.1.5. Identification & Validation
  - 5.2.1.6. Others
- 5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. North America Drug Discovery Informatics Market Outlook, by End User, Value (US$ Mn), 2018 - 2030
- 5.3.1. Key Highlights
  - 5.3.1.1. Pharmaceutical & Biotech Companies
  - 5.3.1.2. Contract Research Organizations
  - 5.3.1.3. Research Institutes
  - 5.3.1.4. Others
- 5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. North America Drug Discovery Informatics Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
- 5.4.1. Key Highlights
  - 5.4.1.1. U.S.
  - 5.4.1.2. Canada
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Europe Drug Discovery Informatics Market Outlook, 2018 - 2030

6.1. Europe Drug Discovery Informatics Market Outlook, by Service Type, Value (US$ Mn), 2018 - 2030
- 6.1.1. Key Highlights
  - 6.1.1.1. In-House
  - 6.1.1.2. Outsourced
- 6.1.2. BPS Analysis/Market Attractiveness Analysis
6.2. Europe Drug Discovery Informatics Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
- 6.2.1. Key Highlights
  - 6.2.1.1. Data Sequencing
  - 6.2.1.2. Target Data Analysis
  - 6.2.1.3. Molecular Docking
  - 6.2.1.4. Molecular Modelling
  - 6.2.1.5. Identification & Validation
  - 6.2.1.6. Others
- 6.2.2. BPS Analysis/Market Attractiveness Analysis
6.3. Europe Drug Discovery Informatics Market Outlook, by End User, Value (US$ Mn), 2018 - 2030
- 6.3.1. Key Highlights
  - 6.3.1.1. Pharmaceutical & Biotech Companies
  - 6.3.1.2. Contract Research Organizations
  - 6.3.1.3. Research Institutes
  - 6.3.1.4. Others
- 6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Europe Drug Discovery Informatics Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
- 6.4.1. Key Highlights
  - 6.4.1.1. Germany
  - 6.4.1.2. France
  - 6.4.1.3. U.K.
  - 6.4.1.4. Italy
  - 6.4.1.5. Spain
  - 6.4.1.6. Rest of Europe
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Asia Pacific Drug Discovery Informatics Market Outlook, 2018 - 2030

7.1. Asia Pacific Drug Discovery Informatics Market Outlook, by Service Type, Value (US$ Mn), 2018 - 2030
- 7.1.1. Key Highlights
  - 7.1.1.1. In-House
  - 7.1.1.2. Outsourced
- 7.1.2. BPS Analysis/Market Attractiveness Analysis
7.2. Asia Pacific Drug Discovery Informatics Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
- 7.2.1. Key Highlights
  - 7.2.1.1. Data Sequencing
  - 7.2.1.2. Target Data Analysis
  - 7.2.1.3. Molecular Docking
  - 7.2.1.4. Molecular Modelling
  - 7.2.1.5. Identification & Validation
  - 7.2.1.6. Others
- 7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Asia Pacific Drug Discovery Informatics Market Outlook, by End User, Value (US$ Mn), 2018 - 2030
- 7.3.1. Key Highlights
  - 7.3.1.1. Pharmaceutical & Biotech Companies
  - 7.3.1.2. Contract Research Organizations
  - 7.3.1.3. Research Institutes
  - 7.3.1.4. Others
- 7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Asia Pacific Drug Discovery Informatics Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
- 7.4.1. Key Highlights
  - 7.4.1.1. China
  - 7.4.1.2. Japan
  - 7.4.1.3. India
  - 7.4.1.4. South Korea
  - 7.4.1.5. Australia & New Zealand
  - 7.4.1.6. Rest of Asia Pacific
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Rest of the World Drug Discovery Informatics Market Outlook, 2018 - 2030

8.1. Rest of the World Drug Discovery Informatics Market Outlook, by Service Type, Value (US$ Mn), 2018 - 2030
- 8.1.1. Key Highlights
  - 8.1.1.1. In-House
  - 8.1.1.2. Outsourced
- 8.1.2. BPS Analysis/Market Attractiveness Analysis
8.2. Rest of the World Drug Discovery Informatics Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
- 8.2.1. Key Highlights
  - 8.2.1.1. Data Sequencing
  - 8.2.1.2. Target Data Analysis
  - 8.2.1.3. Molecular Docking
  - 8.2.1.4. Molecular Modelling
  - 8.2.1.5. Identification & Validation
  - 8.2.1.6. Others
- 8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Rest of the World Drug Discovery Informatics Market Outlook, by End User, Value (US$ Mn), 2018 - 2030
- 8.3.1. Key Highlights
  - 8.3.1.1. Pharmaceutical & Biotech Companies
  - 8.3.1.2. Contract Research Organizations
  - 8.3.1.3. Research Institutes
  - 8.3.1.4. Others
- 8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Rest of the World Drug Discovery Informatics Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
- 8.4.1. Key Highlights
  - 8.4.1.1. Latin America
  - 8.4.1.2. Middle East & Africa
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Company Market Share Analysis
9.2. Company Profiles
- 9.2.1. IBM Corporation
  - 9.2.1.1. Company Overview
  - 9.2.1.2. Financial Overview
  - 9.2.1.3. Service Type Portfolio
  - 9.2.1.4. Recent Developments
- 9.2.2. Charles River Laboratories
- 9.2.3. Accenture PLC
- 9.2.4. Jubilant Biosys
- 9.2.5. PerkinElmer, Inc.
- 9.2.6. Certara, Inc.
- 9.2.7. Exscientia
- 9.2.8. Evotec SE
- 9.2.9. Scilligence ELN
- 9.2.10. Others

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations